Vestal Point Capital, LP Savara Inc Transaction History
Vestal Point Capital, LP
- $1.9 Trillion
- Q2 2025
A detailed history of Vestal Point Capital, LP transactions in Savara Inc stock. As of the latest transaction made, Vestal Point Capital, LP holds 11,015,000 shares of SVRA stock, worth $28.4 Million. This represents 1.32% of its overall portfolio holdings.
Number of Shares
11,015,000
Previous 11,000,000
0.14%
Holding current value
$28.4 Million
Previous $30.5 Billion
17.58%
% of portfolio
1.32%
Previous 2.18%
Shares
5 transactions
Others Institutions Holding SVRA
# of Institutions
128Shares Held
167MCall Options Held
38.7KPut Options Held
0-
Nea Management Company, LLC Timonium, MD24.5MShares$63.1 Million4.63% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA17.6MShares$45.4 Million12.04% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$31.9 Million5.75% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA11.5MShares$29.6 Million1.38% of portfolio
-
Vr Adviser, LLC New York, NY8.88MShares$22.9 Million4.01% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $294M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.